Related Experiment Videos
[Blood lysozyme level and bone marrow granulocyte reserve]
Archivio Per Le Scienze Mediche
|October 1, 1978
Summary
Serum lysozyme levels can predict reduced bone marrow function and potential leukopenia in cancer patients undergoing treatment. This finding highlights a simple method for assessing granulocyte reserve during chemotherapy.
Area of Science:
- Hematology
- Oncology
- Biochemistry
Context:
- Patients with advanced cancers (solid tumors, lymphomas) often undergo chemotherapy and radiation.
- These treatments can impact bone marrow function and lead to complications like leukopenia.
- Monitoring bone marrow granulocyte reserve is crucial for managing treatment toxicity.
Purpose:
- To investigate the relationship between serum lysozyme levels (granulocyte turnover) and bone marrow granulocyte reserve (hydrocortisone test).
- To assess the predictive value of serum lysozyme for bone marrow function in cancer patients undergoing treatment.
Summary:
- The study evaluated 20 patients with advanced cancers receiving cytostatic and/or radiation therapy.
- Serum lysozyme values and the hydrocortisone test were used to assess granulocyte turnover and bone marrow reserve, respectively.
- A correlation was found: high serum lysozyme (indicating accelerated granulocyte turnover) was associated with reduced bone marrow function and reserve.
Impact:
- Serum lysozyme levels offer a simple, non-invasive method to predict reduced bone marrow granulocyte reserve.
- This can help anticipate potential post-chemotherapeutic leukopenia, even when peripheral leukopenia is not yet evident.
- Findings support the use of serum lysozyme as a biomarker in oncology patient management.